Journal: Molecular Biomedicine

Article Title: Deleting fibroblast growth factor 2 in macrophages aggravates septic acute lung injury by increasing M1 polarization and inflammatory cytokine secretion

doi: 10.1186/s43556-024-00203-0

Figure Lengend Snippet: Effect of FGF2 deficiency on BMDM apoptosis and polarization. a – c FGF2 deletion increased BMDM apoptosis. a Apoptosis in BMDM deprived of FBS for 24 h was assessed by flow cytometry ( n = 4). b - c Percentage of PI + Annexin V + and PI- Annexin V + BMDM after starvation. d - k FGF2 deletion in BMDM promoted M1 polarization. d - g Flow cytometric analysis of macrophage markers in BMDM treated with LPS or IL4, including CD86, iNOS, CD206, and Arg1 ( n = 3). h - k The levels of CD86, iNOS, CD206 and Arg1 in BMDM after treatment with LPS or IL4. N represents no treatment; * p < 0.05, vs. WT; Ψ p < 0.05, vs. N + WT; Ω p < 0.05, vs. N + FGF2 KO

Article Snippet: The tissue sections were incubated overnight at 4°C with primary antibodies, including the rabbit polyclonal antibody CD206 (1:200, Cat No. A02285-2, Boster, Wuhan, China), rabbit monoclonal antibody CD86 (1:100, Cat No. BM4121, Boster, Wuhan, China), rabbit polyclonal antibody F4/80 (1:100, Cat No. 29414-1-AP, Proteintech, Wuhan, China), anti-mouse NLRP3 (1:200, Cat No.68102-1-Ig, Proteintech, Wuhan, China), Caspase-1 p20 Rabbit pAb (1:400, Cat No.bs-10743R, Bioss, Beijing, China) and ASC/TMS1 Rabbit PolyAb (1:200, Cat No.10500-1-AP, Proteintech, Wuhan, China).

Techniques: Flow Cytometry

Journal: Molecular Biomedicine

Article Title: Deleting fibroblast growth factor 2 in macrophages aggravates septic acute lung injury by increasing M1 polarization and inflammatory cytokine secretion

doi: 10.1186/s43556-024-00203-0

Figure Lengend Snippet: Mice reconstituted with FGF2 KO macrophages and subjected to CLP demonstrate increased M1 polarization in lung tissue. a - f The presence and levels of CD206, CD86, and F4/80 markers on macrophages within lung tissue were identified and quantitatively assessed using immunofluorescence staining. Bar is 20 μm. * p < 0.05, vs. WT; Δ p < 0.05 vs. WT + LPS; # p < 0.05 vs. FGF2 KO

Article Snippet: The tissue sections were incubated overnight at 4°C with primary antibodies, including the rabbit polyclonal antibody CD206 (1:200, Cat No. A02285-2, Boster, Wuhan, China), rabbit monoclonal antibody CD86 (1:100, Cat No. BM4121, Boster, Wuhan, China), rabbit polyclonal antibody F4/80 (1:100, Cat No. 29414-1-AP, Proteintech, Wuhan, China), anti-mouse NLRP3 (1:200, Cat No.68102-1-Ig, Proteintech, Wuhan, China), Caspase-1 p20 Rabbit pAb (1:400, Cat No.bs-10743R, Bioss, Beijing, China) and ASC/TMS1 Rabbit PolyAb (1:200, Cat No.10500-1-AP, Proteintech, Wuhan, China).

Techniques: Immunofluorescence, Staining

Journal: Cancers

Article Title: CD103 + cDC1 Dendritic Cell Vaccine Therapy for Osteosarcoma Lung Metastases

doi: 10.3390/cancers16193251

Figure Lengend Snippet: Effect of cDCV treatment on infiltrating T-cells and macrophages. Bilateral tumors were stained with anti-CD3/anti-CD8/anti-CD4 ( A – C , K , L ), anti-CD11c/anti-CD103 ( H , I ), anti-CD86 ( F ), or anti-CD163 ( G ) antibodies. Percentage of CD8 + or CD4 + cells out of CD3 + cells were showed in ( D , E ). Percentage of CD103 + cells out of CD11c + cells was showed in ( J ). Positive cells were quantified using Simple PCI software. n = 7–8 mice per group. Data were analyzed using one-way ANOVA test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. cDCV: type 1 CD103 + dendritic cell vaccine; HPF: high-power field; L: left side; PBS: phosphate-buffered saline; R: right side. All values reported represent means ± SEMs. Arrows indicates an example of a positive stained cell in each field.

Article Snippet: Primary antibodies anti-CD86 (1:200) and anti-CD163 (1:200) (CD86, NeoBiotechnologies, Union City, CA, USA; CD163, Abcam, Waltham, MA, USA) were used for the macrophage markers.

Techniques: Staining, Software, Saline

Journal: Advanced healthcare materials

Article Title: Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy

doi: 10.1002/adhm.202002214

Figure Lengend Snippet: Engineered cytokines in clinical development for the treatment of non-malignant diseases.

Article Snippet: Psoriasis Ulcerative colitis , APVO210 , Aptevo Therapeutics , Monomeric IL-10 fused to anti-CD86 antibody , ○ CD86 ○ IL-10R , ○ CD86+ monocytes ○ Dendritic cells , Phase I ( {"type":"clinical-trial","attrs":{"text":"NCT03768219","term_id":"NCT03768219"}} NCT03768219 ) Estimated end date: Sept. 2020 , No results posted , i.v. infusion , [ 115a ].

Techniques: Injection, Irradiation, Control, Residue